BioCryst receives additional NIAID funding for manufacture and development of BCX4430
BioCryst announced that NIAID has exercised two additional options under its contract, which provides for GMP drug substance and drug product manufacture of BCX4430. Exercise of these options includes up to a $2.0 million increase to the existing development contract. September 18, 2014